Moderna Long Term Debt to Equity Trend from 2010 to 2022

MRNA
 Stock
  

USD 171.18  0.63  0.37%   

Moderna Long Term Debt to Equity is increasing over the years with slightly volatile fluctuation. Long Term Debt to Equity is expected to dwindle to 0.0349. From 2010 to 2022 Moderna Long Term Debt to Equity quarterly data regression line had arithmetic mean of 0.023385 and r-squared of  0.75. Moderna Consolidated Income is projected to increase significantly based on the last few years of reporting. The past year's Consolidated Income was at 12.2 Billion. The current year Earning Before Interest and Taxes EBIT is expected to grow to about 14.3 B, whereas Preferred Dividends Income Statement Impact is forecasted to decline to about 19.1 M.
  
Check Moderna financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Moderna main balance sheet or income statement drivers, such as Direct Expenses of 2.8 B, Consolidated Income of 13.2 B or Cost of Revenue of 2.1 B, as well as many exotic indicators such as Long Term Debt to Equity of 0.0349, Calculated Tax Rate of 7.29 or PPandE Turnover of 25.92. Moderna financial statements analysis is a perfect complement when working with Moderna Valuation or Volatility modules. It can also supplement Moderna's financial leverage analysis and stock options assessment as well as various Moderna Technical models . Additionally, see the analysis of Moderna Correlation against competitors.

Moderna Long Term Debt to Equity Breakdown

Showing smoothed Long Term Debt to Equity of Moderna with missing and latest data points interpolated. Moderna's Long Term Debt to Equity historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Moderna's overall financial position and show how it may be relating to other accounts over time.
Long Term Debt to Equity10 Years Trend
Increasing
Slightly volatile
   Long Term Debt to Equity   
Share
       Timeline  

Moderna Long Term Debt to Equity Regression Statistics

Arithmetic Mean 0.023385
Geometric Mean 0.021271
Coefficient Of Variation 47.49
Mean Deviation 0.009424
Median 0.014848
Standard Deviation 0.011105
Sample Variance 0.00012331
Range 0.028048
R-Value 0.86
Mean Square Error 0.00003396
R-Squared 0.75
Significance 0.00013682
Slope 0.002465
Total Sum of Squares 0.00148

Moderna Long Term Debt to Equity History

2017 0.0251
2018 0.0219
2019 0.0329
2020 0.0429
2021 0.0423
2022 0.0349

About Moderna Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Moderna income statement, its balance sheet, and the statement of cash flows. Moderna investors use historical funamental indicators, such as Moderna's Long Term Debt to Equity, to determine how well the company is positioned to perform in the future. Although Moderna investors may use each financial statement separately, they are all related. The changes in Moderna's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Moderna's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Moderna Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Moderna. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for 2022
Long Term Debt to Equity 0.042347  0.0349 
Average Equity8.7 B9.4 B
Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases in the United States, Europe, and internationally. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts. Moderna operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 3200 people.

Moderna Investors Sentiment

The influence of Moderna's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Moderna. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock markets does not have a solid backing from leading economists and market statisticians.
Investor biases related to Moderna's public news can be used to forecast risks associated with investment in Moderna. The trend in average sentiment can be used to explain how an investor holding Moderna can time the market purely based on public headlines and social activities around Moderna. Please note that most equiteis that are difficult to arbitrage are affected by market sentiment the most.
Moderna's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Moderna's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Moderna's news discussions. The higher the estimate score, the more favorable is the investor's outlook on Moderna.

Moderna Implied Volatility

    
  70.55  
Moderna's implied volatility exposes the market's sentiment of Moderna stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Moderna's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Moderna stock will not fluctuate a lot when Moderna's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Moderna in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Moderna's short interest history, or implied volatility extrapolated from Moderna options trading.

Becoming a Better Investor with Macroaxis

Macroaxis puts the power of mathematics on your side. We analyze your portfolios and positions such as Moderna using complex mathematical models and algorithms, but make them easy to understand. There is no real person involved in your portfolio analysis. We perform a number of calculations to compute absolute and relative portfolio volatility, correlation between your assets, value at risk, expected return as well as over 100 different fundamental and technical indicators.

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Moderna Correlation against competitors. Note that the Moderna information on this page should be used as a complementary analysis to other Moderna's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try CEO Directory module to screen CEOs from public companies around the world.

Complementary Tools for Moderna Stock analysis

When running Moderna price analysis, check to measure Moderna's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Moderna is operating at the current time. Most of Moderna's value examination focuses on studying past and present price action to predict the probability of Moderna's future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Moderna's price. Additionally, you may evaluate how the addition of Moderna to your portfolios can decrease your overall portfolio volatility.
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Go
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Go
Money Managers
Screen money managers from public funds and ETFs managed around the world
Go
Stock Tickers
Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites
Go
Equity Valuation
Check real value of public entities based on technical and fundamental data
Go
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Go
Transaction History
View history of all your transactions and understand their impact on performance
Go
Is Moderna's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Moderna. If investors know Moderna will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Moderna listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
-0.19
Market Capitalization
67.2 B
Quarterly Revenue Growth YOY
0.091
Return On Assets
0.46
Return On Equity
1.14
The market value of Moderna is measured differently than its book value, which is the value of Moderna that is recorded on the company's balance sheet. Investors also form their own opinion of Moderna's value that differs from its market value or its book value, called intrinsic value, which is Moderna's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Moderna's market value can be influenced by many factors that don't directly affect Moderna's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Moderna's value and its price as these two are different measures arrived at by different means. Investors typically determine Moderna value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Moderna's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.